Your browser doesn't support javascript.
loading
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.
Lapidari, Pietro; Djehal, Nardjes; Havas, Julie; Gbenou, Arnauld; Martin, Elise; Charles, Cecile; Dauchy, Sarah; Pistilli, Barbara; Cadeau, Claire; Bertaut, Aurélie; Everhard, Sibille; Martin, Anne-Laure; Coutant, Charles; Cottu, Paul; Menvielle, Gwenn; Dumas, Agnes; Andre, Fabrice; Michiels, Stefan; Vaz-Luis, Ines; Di Meglio, Antonio.
Afiliação
  • Lapidari P; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.
  • Djehal N; Univesità Degli Studi di Pavia, Pavia, Italy.
  • Havas J; Medical Oncology, Gustave Roussy, Villejuif, France.
  • Gbenou A; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.
  • Martin E; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.
  • Charles C; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.
  • Dauchy S; Bordeaux Public Health, Université de Bordeaux, U1219, Bordeaux, France.
  • Pistilli B; Département Interdisciplinaire de Soins de Support aux Patients en Onco-hématologie, Gustave Roussy, Villejuif, France.
  • Cadeau C; Medical Oncology, Gustave Roussy, Villejuif, France.
  • Bertaut A; Harvard Medical School, Boston, MA, USA.
  • Everhard S; Centre Georges-François Leclerc, Methodology and Biostatistic Unit, Dijon, France.
  • Martin AL; Unicancer, Paris, France.
  • Coutant C; Unicancer, Paris, France.
  • Cottu P; Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
  • Menvielle G; Medical Oncology, Institut Curie, Paris, France.
  • Dumas A; Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Andre F; ECEVE UMR 1123, Université de Paris, Paris, France.
  • Michiels S; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.
  • Vaz-Luis I; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
  • Di Meglio A; Inserm, University Paris-Saclay, Labeled «Ligue Contre le Cancer¼, Oncostat U1018, Villejuif, France.
Breast Cancer Res Treat ; 190(3): 517-529, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34559354
ABSTRACT

BACKGROUND:

Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF.

METHODS:

Women with stage I-III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCAM use.

RESULTS:

Among 5237 women, 23.0% reported OCAM use overall (49.3% at diagnosis, 50.7% starting post-diagnosis), mostly homeopathy (65.4%). Mean (SD) CRF score was 27.6 (24.0) at diagnosis and 35.1 (25.3) at post-diagnosis. More intense CRF was consistently associated with OCAM use at diagnosis and post-diagnosis [adjusted odds ratio (aOR) for 10-point increase 1.05 (95% Confidence interval 1.01-1.09) and 1.04 (1.01-1.09) vs. never use, respectively]. Odds of using OCAM at diagnosis were higher among older [for 5-year increase, 1.09 (1.04-1.14)] and more educated patients [college vs. primary 1.80 (1.27-2.55)]. Women with income > 3000 [vs. < 1500 euros/month, 1.44 (1.02-2.03)], anxiety [vs. not, 1.25 (1.01-1.54)], and those receiving chemotherapy [vs. not, 1.32 (1.04-1.68)] had higher odds of using OCAM post-diagnosis.

CONCLUSION:

One-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapias Complementares / Neoplasias da Mama Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapias Complementares / Neoplasias da Mama Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article